Poor
Needs Revision
Patient Risk:
Low
Summary
Most claims concern pricing, reimbursement, or subcutaneous TECENTRIQ, none of which are addressed by the supplied label. The label supports only that TECENTRIQ is atezolizumab supplied for intravenous use and provides indication-specific intravenous dosing; it does not establish pricing, subcutaneous formulation, or comparative product equivalence.
Category Scores
Accurate Statements
Unsupported Statements
Tecentriq SC refers to the subcutaneous formulation of atezolizumab.
The supplied label describes TECENTRIQ only as an intravenous injection and does not describe a subcutaneous formulation.
The price of Tecentriq depends on the country, payer, treatment regimen, and whether the price is the list price or the amount billed after discounts.
The label contains no information about price, geography, payers, discounts, or billing.
Public price references for Tecentriq may reflect different package sizes or reimbursement settings.
The label describes vial sizes and strengths but does not address public price references or reimbursement settings.
The subcutaneous product can be priced differently from the intravenous version.
The label does not describe a subcutaneous product or comparative pricing.
Differences in manufacturer, packaging, and dosing administration cost structure can contribute to different pricing between subcutaneous and intravenous Tecentriq.
The label contains no manufacturer-cost, packaging-cost, administration-cost, or comparative pricing information.
The subcutaneous and intravenous products contain the same medicine, atezolizumab.
The label identifies TECENTRIQ as atezolizumab but does not describe a subcutaneous product or establish its composition or equivalence to the intravenous product.
Total Tecentriq cost is driven by the milligrams per dose and how often it is administered for the specific cancer indication.
The label provides indication-specific intravenous doses and administration intervals but does not discuss treatment cost or state that these factors drive cost.
Subcutaneous dosing is weight- and regimen-dependent in many immunotherapy schedules.
The supplied label does not describe subcutaneous dosing. It describes mostly fixed intravenous regimens, with weight-based dosing only for pediatric ASPS.
List price is the price set by the manufacturer.
The label does not define or discuss list price or manufacturer-set pricing.
Patient out-of-pocket cost can reflect insurance, copayments, or assistance.
The label contains no information about insurance, copayments, patient assistance, or out-of-pocket costs.
Contradictions
Important Omissions
The response should have stated that the supplied label covers TECENTRIQ for intravenous use only and provides no pricing or reimbursement information.
Importance:
High
The response should have distinguished the label-supported intravenous dosing information from unsupported claims about subcutaneous dosing and subcutaneous product availability.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are primarily economic and product-description claims and do not provide a treatment recommendation. However, describing a subcutaneous formulation or dosing without support from the supplied label could cause product or administration confusion.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response makes numerous pricing and subcutaneous-product claims that cannot be verified from the supplied prescribing information.
Suggested Improvement
Limit label-based statements to the supported facts: TECENTRIQ is atezolizumab supplied as an intravenous injection, with the labeled vial strengths and intravenous dosing regimens. Explicitly state that pricing, reimbursement, and any subcutaneous formulation are not addressed by the supplied label.